Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
Е. Л. Насонов(Association of Rheumatologists of Russia), A. Yu. Zimenko(Surgut State University), I. B. Vinogradova(Ulyanovsk Regional Clinical Hospital), Б. С. Белов(Unknown), E. S. Aronova, Д. И. Абдулганиева(Kazan State Medical University), E. Sokol, Г. И. Гриднева, А. М. Лила(Russian Medical Academy of Continuous Professional Education), A. Kudryavtseva, А. В. Торгашина
Cited by 14
Related Papers
RATIONAL USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. CLINICAL GUIDELINES
|Rheumatology Science and Practice|2018|151
GENERAL PRINCIPLES OF TREATMENT FOR MUSCULOSKELETAL PAIN: INTERDISCIPLINARY CONSENSUS
|Rheumatology Science and Practice (Nauchno-prakticheskaya revmatologiya) (IMA Press)|2016|62
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
|Rheumatology Science and Practice|2021|54
COVID-19: the new challenge for rheumatologists
|Modern Rheumatology Journal|2020|30
Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova)
|Meditsinskiy sovet = Medical Council|2019|14